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OBJECTIVE—Because adipose tissue is highly vascularized,
modifying adipose tissue vasculature may provide a novel
method for reducing body fat. A peptide sequence that elicits
apoptosis of endothelium in white fat potently reduced body
weight. We sought to determine how inhibiting adipose tissue
vasculature changes key aspects of energy balance regulation
and the neuroendocrine system that maintains energy balance.
RESEARCH DESIGN AND METHODS—Lean and obese mice
or rats were treated with proapoptotic peptide for 4 or 27 days.
Daily energy intake and expenditure were measured in mice on a
low- (LFD) or high-fat diet (HFD) and in rats on a HFD. A
conditioned taste aversion test was performed to assess whether
proapoptotic peptide produces visceral illness. Hypothalamic neu-
ropeptide Y, agouti-related peptide, and proopiomelanocoritin
(POMC) mRNA expression and plasma leptin levels were evaluated.
RESULTS—Proapoptotic peptide completely reversed HFD-in-
duced obesity in mice and reduced body weight in mice and rats
on a HFD but not in those on a LFD. Fat loss occurred with no
change of energy expenditure but reduced food intake that
occurred without signs of illness and despite reduced circulating
leptin and reduced hypothalamic POMC gene expression, indi-
cating that the decrease in food intake is independent of the
action of leptin.
CONCLUSIONS—These experiments provide compelling evi-
dence for a previously unknown relationship between the status
of adipose tissue vasculature and the regulation of food intake.
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T
he prevalence of overweight and obesity among
adults and children is increasing throughout the
developed world (1,2), highlighting the enor-
mous need to ﬁnd new therapeutic strategies
that allow for safe and durable weight loss. However,
chronic weight loss is difﬁcult to achieve because of
elaborate neuroendocrine mechanisms that work against
sustained negative energy balance (3–5). We herein
present data on a promising strategy to induce signiﬁcant
weight loss by inhibiting angiogenesis in adipose tissue
(6–8). White adipose tissue is highly vascularized, and
both the expansion and maintenance of adipose tissue
depend on a continued ability to build the necessary
vasculature to support a large volume of tissue (9,10). In
this way, increasing adipose mass can be compared with
an expanding tumor because both tissues require rapid
angiogenesis. Given this dependence on the capacity to
make new blood vessels, one successful strategy for
reducing the size of tumors has been to inhibit angiogen-
esis and thereby starve tumors (6–8).
Pharmacological inhibitors of angiogenesis such as O-
(chloracetyl-carbamoyl) fumagillol (TNP-470) and an-
giostatin reduce fat mass in obese and leptin-deﬁcient
mice (6,8). Adopting an alternative strategy, Kolonin et al.
(7) used phage display to identify a peptide sequence that
speciﬁcally homes to endothelial cells in white adipose
tissue by binding to the cell-surface molecule prohibitin.
This peptide sequence was then fused to a proapoptotic
sequence that, when internalized in a cell, initiates apo-
ptosis. Thus, they developed a “proapoptotic peptide” that
speciﬁcally reduces endothelium and vasculature in white
adipose tissue. When administered over a 4-week period,
the proapoptotic peptide reduced body weight and fat
mass of ob/ob mice and mice with diet-induced obesity
without eliciting abnormal fat absorption. That report did
not identify how the energy-balance equation was modi-
ﬁed to achieve the dramatic weight loss (3,4). Thus, the
present experiments sought to determine the relationship
between adipose tissue vasculature and regulation of
energy balance by identifying mechanisms of energy bal-
ance by which apoptosis selectively in endothelium of
white adipose tissue results in profound weight loss.
RESEARCH DESIGN AND METHODS
Male C57Bl/6 mice obtained from The Jackson Laboratories at 8 weeks of age
or adult male Long-Evans rats from Harlan (Indianapolis, IL) were housed
individually in standard mouse or rat cages with a 12-h light/12-h dark cycle.
They had ad lib access to either a high-fat diet (HFD) providing 40% calories
as fat (D03082706; Research Diet, NJ) or a low-fat diet (LFD) with 4% fat
(D03082705) for 8 weeks as previously described (11). After 8 weeks on the
HFD, half of those mice were administered 3 mg/kg of proapoptotic peptide
[CKGGRAKDC-GG-D(KLAKLAK)2] in 0.5% DMSO/saline, and half were admin-
istered the same dose of the control peptide (CKGGRAKDC) subcutaneously
daily just before dark for 27 days as previously described (7). Lean mice were
injected with 0.5% DMSO/saline. A second cohort of comparable C57Bl/6 mice
was made obese as a result of 127 days on a HFD (D012451; Research Diet).
Eight mice were treated with control peptide or proapoptotic peptide once
daily (44 g) on the HFD in calorimetry chambers for 4 days, and another
eight mice were injected with with vehicle or proapoptotic peptide in the
short-term study. To determine the differential effect of the proapoptotic
peptide on energy intake of mice on the LFD and HFD, a third, fourth, and ﬁfth
cohort of comparable C57Bl/6 mice were prepared by being fed the HFD
(D03082706; Research Diet) or the LFD (D03082705) for 3 or 4 months. For the
experiments with rats, adult male Long-Evans rats were injected with 1.5
mg/kg of proapoptotic peptide or vehicle (saline) for 4 days after they were
put on the HFD for 3 months. All animal protocols were approved by the
University of Cincinnati Institutional Animal Care and Use Committee.
Food intake and body-weight measurements. Food intake and body weight
were measured daily. The biological kinetics of the proapoptotic peptide targeting
adipose tissue are unusual. Other treatments that have used the (KLAKLAK)2with
other targeting sequences have elicited apoptosis after 24 h (12).
Determination of energy expenditure and respiratory quotient. Energy
expenditure was measured by indirect calorimetry. For the 27-day experi-
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diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 907ment, obese mice of each group (n  8/group) were placed individually into
calorimetry chambers (Oxymax System; Columbus Instruments) with food
and water available for determining O2 consumption and CO2 production.
Mice were monitored for 22 h on days 10, 11, and 12. For the acute study,
obese mice of each group (n  4/group) were acclimated to the metabolic
chamber (Physioscan Metabolic System; Accuscan Instruments) for 4 days
prior to treatment. O2 consumption and CO2 production were then determined
for 22 h/day throughout the experiment. VO2 consumption was adjusted for
lean body mass as determined by nuclear magnetic resonance, and the
VCO2-to-VO2 ratio (RQ ratio) was calculated by dividing VCO2 production by
VO2 consumption.
Conditioned taste aversion protocol. To determine whether the proapop-
totic peptide elicits visceral illness, we used a conditioned taste aversion
(CTA) paradigm as previously described (13). Mice ad libitum fed a HFD diet
(vehicle, n  6; control peptide, n  6; and proapoptotic peptide, n  12) were
allowed to drink water or Kool-Aid for1ha tt h esame time each day. On
training days 1, 2, and 4, all animals had access to two bottles of water for 1
h/day. On training day 3, all animals had 1-h access to one of two novel ﬂavors
(1% saccharin ﬂavored with either grape or cherry Kool-Aid). Immediately
after access to the ﬂavor, each mouse was subcutaneously injected with 0.15
mol/l NaCl at a volume of 1% of body weight. On training day 5, each mouse
had 1 h access to the alternate novel ﬂavor in both bottles and received a
subcutaneous injection of vehicle (0.5% DMSO/saline), control peptide, or
proapoptotic peptide at the same volume. The 2-day training with saline or one
of the test solutions was repeated, and on the subsequent 3 days the mice had
1 h access to two bottles of water. On the test day, the mice were given both
ﬂavors in separate bottles. Intake was recorded at 30, 60, 90, and 120 min and
at 24 h. The relative positions of the two ﬂavors were changed at each
measurement time point to ensure that a side preference would not inﬂuence
the data. The preference ratio was calculated as the ratio of ﬂuid intake of the
ﬂavor paired with a test solution over total ﬂuid intake. We used 0.15 mol/l
LiCl-treated mice as a positive control.
Intracerebral third-ventricular injection of proapoptotic peptide. Un-
der ketamine and xylazine anesthesia, 14 rats received cannula in the third
cerebral ventricle (14). On the test day, food was removed 3 h before dark, and
the rats received 30 g proapoptotic peptide in 2 l of 0.9% physiological
saline or vehicle. Food was returned just before dark and intake measured at
2, 4, 6, 24, and 48 h. Body weight was measured at 24 and 48 h.
Body composition analysis. Body composition was analyzed with a quanti-
tative nuclear magnetic resonance (Echo MRI Whole Body Composition
Analyzer; Echo Medical Systems) (15) on days 12 and 23 for the longer-term
study and on day 4 in the acute study.
Leptin, adiponectin, and resistin measurement. Blood samples were
taken by cardiac puncture from mice fasted for 4 h. Leptin was determined
using a rat leptin RIA kit (Linco, St. Louis, MO). Adiponectin was determined
using a mouse/rat adiponectin ELISA kit (B-Bridge International). Resistin
was measured using a mouse resistin ELISA kit (Millipore).
Hypothalamic gene expression. As previously described (16), mice were
killed during the light phase after a 4-h fast. The brain was quickly removed
and stored in RNA later (Ambion, Austin, TX). Total RNA was isolated and
cDNA synthesized using iScript and veriﬁed by L32 ampliﬁcation products. All
RT-PCR were performed using Failsafe PCR kits (EPICENTRE Biotechnolo-
gies). Mouse quantitative PCR primer sequences are in Table 1. Each primer
set was optimized such that the correlation was 0.99–1.0 and the PCR
efﬁciency was 90–100%. PCR was performed in triplicated using an iCycler and
the iQ SYBR Green Supermix (Bio-rad Laboratories) with two-step ampliﬁcation
(95°C for 10 sec and annealing temperature for 30 sec) for 40 cycles. L32 was
ampliﬁed from every sample for use as an endogenous control. For the data
analysis, the threshold cycle (CT) of each set of triplicates was calculated. To
normalize the data, the CT was calculated for each sample by subtracting the
average CT of L32 from the average CT of the gene of interest. The CT was
averaged for the control group and was then subtracted from the CT of each
experimental sample to generate the CT. The CT was then used to calculate
the fold difference, 2
CT (16,17).
Determination of adipose leptin mRNA expression. Adipose tissue was
quickly removed and stored in RNA later. Total RNA was isolated using Tri
Reagent (Medical Research Center) and repuriﬁed using an RNeasy MinElute
Cleanup Kit (Qiagen). After verifying the integrity of the RNA, target RNA was
prepared using the Ovation Biotin RNA Ampliﬁcation and Labeling System
(Nugen) from 20 ng total RNA from each mouse and hybridized to Affymetirx
Mouse Genome 430 2.0 microarrays. The data were analyzed to identify
differentially expressed genes among vehicle-injected LFD (LF-V) mice, con-
trol peptide–injected HFD (HF-CP) mice, and proapoptotic peptide–treated
HFD (HF-PP) mice. Speciﬁcally, the differences were estimated for HF-PP
versus HF-CP, HF-CP versus LF-V, and HF-PP versus LF-V. Analysis was
performed using R statistical software and the limma Bioconductor package
(18). All steps of data preprocessing, including background correction,
normalization, and expression set summaries, were performed using robust
multichip analysis (RMA). Estimated fold changes were calculated using
ANOVA, and resulting t statistics from each comparison were modiﬁed using
an intensity-based empirical Bayes method (19).
Statistical analyses. All data are expressed as means  SEM. Body weight,
food intake, O2 consumption, and RQ ratio in the short- and long-term studies
were analyzed by repeated two-way ANOVA. CTA data, O2 consumption, and
leptin were analyzed by one-way ANOVA. Differences in gene expression,
leptin, adiponectin, and resistin were determined by Student’s t test. Signiﬁ-
cant ANOVAs were followed by post hoc Tukey’s test. P values 0.05 were
considered signiﬁcant.
RESULTS
Proapoptotic peptide and energy intake. C57Bl/6 mice
were placed on a LFD or beginning at 8 weeks of age.
HFD-fed mice were 20% heavier than mice on the LFD
after 8 weeks. HFD-fed mice were subcutaneously injected
with control peptide or proapoptotic peptide, and LFD-fed
mice were injected with vehicle. Consistent with a previ-
ous report, HF-PP mice lost signiﬁcant body weight over
27 days of treatment compared with HF-CP mice. Body
weight of HF-PP mice was not signiﬁcantly different from
that of LF-V mice (Fig. 1A). The loss of body weight
induced by the proapoptotic peptide was positively corre-
lated with initial body weight (r
2  0.550; P  0.05) (Fig.
1B). Thus, the heavier mice lost more weight.
A key question pertains to the cause of the reduction in
body weight. ANOVA revealed a signiﬁcant interaction be-
tween treatment and time on cumulative energy intake, and
Tukey’s post hoc test indicated that cumulative energy intake
was signiﬁcantly decreased in HF-PP mice compared with
HF-CP mice throughout the experiment and beginning at day
7 (Fig. 1C). A closer analysis revealed that the energy intake
of HF-PP mice was signiﬁcantly lower than that of HF-CP
TABLE 1
Mouse quantitative PCR primer sequences
Gene Mouse Q-PCR primer sequences
Temperature
(°C)
L32 61.2
Forward 5-GCCAGGAGACGACAAAAAT
Reverse 5-AATCCTCTTGCCCTGATCC
AgRP 61.2
Forward 5-TGTGTAAGGCTGCACGAGTC
Reverse 5-GGCAGTAGCAAAAGGCATTG
NPY 61.2
Forward 5-AGGCTTGAAGACCCTTCCAT
Reverse 5-ACAGGCAGACTGGTTTCAGG
POMC 61.2
Forward 5-GAGTTCAAGAGGGAGCTGGA
Reverse 5-GGTCATGAAGCCACCGTAAC
Lep 61.2
Forward 5-TTCACACACGCAGTCGGTAT
Reverse 5-GCTGGTGAGGACCTGTTGAT
LPL 55
Forward 5-TTCCAGCCAGGATGCAACA
Reverse 5-GGTCCACGTCTCCGAGTCC
FABP4 55.8
Forward 5-CATCAGCGTAAATGGGGATT
Reverse 5-CTTGTGGAAGTCACGCCTTT
FASN 58.7
Forward 5-TTGCTGGCACTACAGAATGC
Reverse 5-AACAGCCTCAGAGCGACAAT
ACACA 61.4
Forward 5-GAGAGGGGTCAAGTCCTTCC
Reverse 5-CTGCTGCCGTCATAAGACAA
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treatment but not on the ﬁrst day of treatment (Fig. 1D).
In a separate experiment comparing mice on both diets
(LFD vs. HFD 34.0  1.1 g vs. 44.5  0.6 g of initial body
weight), the effect of the proapoptotic peptide on energy
intake and body weight was greater in HFD mice than in
LFD mice on day two, suggesting that the peptide reduces
energy intake by directly acting on adipose tissue (Fig. 2).
To determine whether rats respond comparably, rats fed
the HFD for 3 months were treated with the proapoptotic
peptide for 4 days. Energy intake and body weight of
PP-treated rats were signiﬁcantly decreased compared
with those of vehicle-injected rats in a pattern similar to
what occurred in mice (Fig. 1D, F, and G), indicating that
both mice and rats are sensitive to the weight- and food
intake–reducing effects of PP (Fig. 2B).
Direct effect of proapoptotic peptide in hypothala-
mus on food intake. To determine whether the proapop-
totic peptide directly affects the central nervous system
(CNS), we compared food intake and change of body
weight after administration of 30 g proapoptotic peptide
or vehicle into the third ventricle of rats. There was no
difference in food intake or body weight after proapoptotic
peptide administration compared with vehicle (supple-
mental Fig. 1A and B, available in an online appendix
[http://diabetes.diabetesjournals.org/cgi/content/full/db09-
1141/DC1]). We further explored whether the PP might
target the CNS by examining transferase-mediated dUTP
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FIG. 1. Effect of 27 days of proapoptotic peptide administration on energy balance in mice and of 4 days’ proapoptotic peptide administration in
rats. A: Change (growth curve) in body weight of LFD- or HFD-fed C57Bl/6 mice. The body weight of HFD-fed C57Bl/6 mice was greatly decreased
after 27 days of subcutaneous treatment with proapoptotic peptide (150 g) compared with that of mice treated with equimolar amount of
control peptide and not signiﬁcantly different from that of LFD-fed C57Bl/6 mice injected with vehicle (0.5% DMSO/saline). B: Negative
correlation between initial body weight and body weight gain over 14 days’ treatment. C: Cumulative energy intake was signiﬁcantly decreased
in HF-PP mice throughout the treatment compared with that in HF-CP mice. D: Change over 24 h in energy intake on the ﬁrst (left panel) and
second (right panel) days of treatment. The energy intake was signiﬁcantly different in HF-PP mice from 8 h after treatment on the second day
of treatment compared with that in HF-CP mice but not on the ﬁrst day. LF-V, n  8; HF-CP, n  8; HF-PP, n  8. E–G: Effect of the proapoptotic
peptide on body weight (E), cumulative energy intake (F), and 24-h change in energy intake on the second day of treatment (G) in rats. HF-V,
n  12; HF-PP, n  12.
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totic peptide–treated mice. We observed no TUNEL stain-
ing in key brain regions, indicating that there was no
obvious apoptosis in the hypothalamus.
CTA. To determine whether the reduction of food intake
following administration of the proapoptotic peptide is
associated with visceral illness, we assessed the ability of
proapoptotic peptide to produce a CTA using the toxin
LiCl as a positive control. The preference ratio of Kool-aid
intake among LF-V, HF-CP, and HF-PP mice was not
different at any time point. In contrast, LiCl caused a
robust CTA (P  0.001) (Fig. 3A). There are limitations to
CTAs with the proapoptotic peptide because the effect on
food intake takes time to become apparent. However,
there were clear differences between LiCl and proapop-
totic peptide. Further, proapoptotic peptide did not signif-
icantly reduce intake in LFD mice (Fig. 2).
Proapoptotic peptide and energy expenditure. Energy
expenditure in the indirect calorimeter of HF-PP mice
expressed as O2 consumption adjusted for lean mass was
not signiﬁcantly different from that of HF-CP mice during
the second week of treatment (Fig. 3B). To determine a
possible effect of proapoptotic peptide on energy balance
earlier in treatment, a heavier cohort of HFD mice (44.6 
0.6 g at the start) was acclimated to indirect calorimetry
chambers before receiving the proapototic or control
peptide for 4 days. Body-weight loss was signiﬁcantly
greater in HF-PP mice on days three and four of treatment
than in HF-CP mice (Fig. 4A). Cumulative energy intake of
HF-PP mice was also signiﬁcantly decreased on days three
and four, with no change in energy expenditure, compared
with that of HF-CP mice (Fig. 4B and C). However, the
nocturnal RQ ratio was signiﬁcantly reduced on days three
and four, consistent with the reduction in energy intake,
indicating that HF-PP mice oxidized a greater proportion
of fat than HF-CP mice (Fig. 4C).
Proapoptotic peptide and adiposity. The decreased
body weight was mainly attributable to loss of fat mass in
the longer-term study; however, there was no signiﬁcant
difference of fat and lean mass in the four-day study (Fig.
5A and B). Consistent with the reduction in fat mass,
serum leptin levels were signiﬁcantly decreased in the
longer-term study, as was leptin mRNA expression in
adipose tissue by 1.3-fold as measured by Affymetrix gene
chip analysis (intensity-based empirical Bayes method
[0.0011]) (Fig. 5C and E). Adipose leptin mRNA expression
was signiﬁcantly decreased (P  0.01) after 3 days of
treatment, whereas serum leptin level was not changed in
the 4-day study (Fig. 5D and F). There was no difference
in serum adiponectin level and signiﬁcant decrease in
serum resistin level in the 4-day study, eliminating them as
factors that affect food intake (20–25) (Fig. 6A and B).
To determine how adipose tissue lipid metabolism is
changed by targeting adipose tissue vasculature, we mea-
sured gene expression levels of lipoprotein lipase (LPL),
fatty acid–binding protein 4 (FABP4), fatty acid synthase
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pose tissue after 3 days of treatment in a separate cohort
of HF-PF mice. The pair feeding was performed every 12 h
to better match the pattern of caloric intake between
groups. There was a signiﬁcant decrease in FASN of
HF-PP mice and HF-PF mice compared with that of HF-V
mice and a nonsigniﬁcant trend toward a reduction in
ACACA compared with HF-V mice (P  0.06). FABP4 of
HF-PF mice was signiﬁcantly increased compared with
that of HF-V mice, and LPL of HF-PF mice had a trend to
be increased compared with that of HF-PP mice (P 
0.08), whereas there was no signiﬁcant difference in LPL
and FABP4 between HF-V mice and HF-PP mice (Fig. 6C).
These data suggest that the changes in lipid metabolism
caused by the proapoptotic peptide are not just the result
of reduced food intake.
Proapoptotic peptide and hypothalamic gene expres-
sion. Many genes in the hypothalamus are regulated by
energy balance and are thought to play a key role in
regulating food intake and energy expenditure. We there-
fore evaluated hypothalamic neuropeptide Y (NPY), ag-
outi-related peptide (AgRP), and proopiomelanocoritin
(POMC) gene expression after 4 and 27 days of treatment
with the proapoptotic peptide. POMC gene expression was
signiﬁcantly decreased in HF-PP mice with no change in
NPY or AgRP gene expression after 27 days, although
there were no overall signiﬁcant differences among LF-V,
HF-CP, and HF-PP mice by one-way ANOVA (Fig. 7A).
Consistent with this, there was a tendency toward de-
creased POMC gene expression in the hypothalamus after
4 days of treatment with the proapoptotic peptide (P 
0.06) and, again, no change of NPY or AgRP gene expres-
sion (Fig. 7B).
DISCUSSION
These results demonstrate that administering a peptide
that produces apoptosis uniquely in the endothelium of
white adipose tissue can produce profound reductions in
body weight that are primarily in the form of reduced body
fat (Fig. 5A). This reduction in body weight occurs through
a decrease in food intake without signs of illness. In
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the body weight and nearly the body fat of mice main-
tained on a LFD. The ability to completely reverse diet-
induced obesity is a result achieved by few other
treatments (26–30) and replicates the original reports
using this proapoptotic peptide (7).
In the original description of the effect of the proapop-
totic peptide, the large weight loss could not be accounted
for by increased energy expenditure, decreased energy
intake, or a decreased ability to extract calories from food
(7). While we observed no change in energy expenditure in
either the short or the long term, by the second week of
treatment, HF-PP mice were ingesting fewer calories than
HF-CP mice (Figs. 1 and 2). In fact, most (76%) of the
reduction in body mass can be accounted for by reduced
energy intake over the 27-day study when the difference in
ingested calories between HP-CP mice and HF-PP mice is
compared with the calculated calories from the difference
in body composition.
The pattern of changes in intake was distinctive. There
was no reduction in food intake in the HF-PP mice during
the ﬁrst day of treatment. However, beginning 8 h after the
second daily administration, hypophagia was apparent and
lasted for the duration of that day and thereafter, and a
similar pattern of hypophagia and weight loss occurred in
rats. The effect of the proapoptotic peptide to reduce food
intake and body weight was more potent in mice on a HFD
than in those on a LFD (Fig. 2A) and was not due to a
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These data suggest that the enlarged adipose tissue mass
caused by consumption of the HFD is a primary target of
the proapoptotic peptide. Interestingly, this robust de-
crease in intake occurred despite lower adiposity and
lower circulating leptin level (Fig. 5). Low leptin levels,
such as after fasting leptin deﬁciency or genetic lipodys-
trophy, are associated with increased food intake (31,32)
Some data link other adipokines such as adiponectin and
resistin to the regulation of food intake (20–25). However,
those adipokines also do not appear to be critical to the
observed effects on food intake. Thus, we propose that
there is a signal or signals originating from adipose tissue
vasculature, which override the effects of low-circulating
leptin levels. These results are in contrast to the original
report with the proapoptotic peptide, where no changes in
intake were observed (7). However, we have observed this
phenomenon clearly in multiple experiments and multiple
species and that the failure to observe this in the original
report was likely due to not measuring food intake with
sufﬁcient accuracy at the most important time points.
Whenever animals eat less food and lose body weight
following administration of a novel compound, it is impor-
tant to determine whether the reduced intake is secondary
to visceral illness. While the overall pattern of intake
elicited by the proapoptotic peptide suggests that this is
unlikely, this possibility was evaluated directly by compar-
ing the effect of the peptide to produce a CTA with that of
an anorexic dose of lithium chloride. Neither the proapop-
totic peptide nor the control peptide inﬂuenced preference
for the ﬂavor with which it had been paired (Fig. 3A).
Combined with the present data showing that the proapop-
totic peptide is less effective in lean mice, this suggests
that the anorexia is not secondary to toxic effects of the
treatment.
Interestingly, the effect of the proapoptotic peptide on
expression of genes related to lipid metabolism in adipose
tissue was different than that in pair-fed mice. Fasting
decreases adipose tissue LPL in lean rats, and fasting-
induced decrease in adipose LPL is blunted in obese rats
(33). Adipose tissue LPL is increased in obese rats and
humans, and weight reduction further increases or cannot
normalize adipose tissue LPL in obese rats or humans
(34–38). HF-PF mice had a tendency toward increased
adipose tissue LPL expression compared with HF-PP
mice. mRNA expression of FABP4 and LPL in HF-PP mice
was similar to that in HF-V mice. Genes such as FASN and
ACACA, which are linked to lipogenesis, decreased equiv-
alently in HF-PP mice and HF-PF mice.
Given that reduced food intake appears responsible for
most of the weight loss, we assessed the effect of the
apoptotic peptide on CNS circuits that inﬂuence food
ingestion. A key component of these circuits is a group of
neuropeptides in the arcuate nucleus of the hypothalamus
that are direct targets of leptin (3,5). There are two distinct
populations of these arcuate neurons: one synthesizing the
orexigenic peptides NPY and AgRP and the other synthe-
sizing the anorexic peptide -melanocyte–stimulating hor-
Day 4
HF-CP HF-PP
0
1
2
3
A
d
i
p
o
n
e
c
t
i
n
 
(
n
g
/
m
l
)
Day 4
* * *
*
HF-CP HF-PP
0
5
10
15
20
25
R
e
s
i
s
t
i
n
 
(
n
g
/
m
l
)
Adipose Genes Related
to Lipid Metabolism on Day 3
LPL
FABP4
FASN
ACACA
0.0
0.5
1.0
1.5 HF-V
HF-PP
HF-PF
R
e
l
a
t
i
v
e
 
G
e
n
e
E
x
p
r
e
s
s
i
o
n
A BC
FIG. 6. Effect of proapoptotic peptide on serum adiponectin (A) and resistin (B) levels after 4 days of treatment and expression of genes related
to lipid metabolism in adipose tissue after 3 days of treatment (C). Pair feeding was performed every 12 h for 3 days. All data are represented
as means  SEM. HF-V, n  8; HF-CP, n  8; HF-PP, n  8; HF-PF, n  8. *P < 0.05.
Hypothalamic mRNA
Expression on Day 27
NPY AgRP POMC
0.0
0.5
1.0
1.5
2.0 LF-V
*
HF-CP
HF-PP
R
e
l
a
t
i
v
e
 
G
e
n
e
E
x
p
r
e
s
s
i
o
n
R
e
l
a
t
i
v
e
 
G
e
n
e
E
x
p
r
e
s
s
i
o
n
 
Hypothalamic mRNA
Expression on Day 4
NPY AgRP POMC
0.0
0.5
1.0
1.5 HF-CP
HF-PP
A B
FIG. 7. Effect of 27-day (A) or 4-day (B) treatment with proapoptotic peptide on hypothalamic NPY, AgRP, and POMC mRNA. All data are
represented as means  SEM. LF-V, n  8; HF-CP, n  8; HF-PP, n  8. *P < 0.05.
D.-H. KIM, S.C. WOODS, AND R.J. SEELEY
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 913mone from the precursor molecule POMC. Expression of
NPY and AgRP is inhibited by leptin (39,40), whereas
expression of POMC is increased by leptin (41–43). There
was no change in either NPY or AgRP gene expression at
either time point assessed. In contrast, POMC gene expres-
sion was signiﬁcantly reduced chronically and there was a
trend toward a decrease after just 4 days of peptide
administration. Reduced POMC gene expression is likely
secondary to reduced intake, body weight, and leptin and
therefore cannot account for the reduced food intake. The
leptin-independent action of the adipose tissue–speciﬁc
angiogenesis inhibitor proapoptotic peptide is consistent
with a previous ﬁnding that a systemic angiogenesis
inhibitor such as TNP-470 reduces body weight and intake
in ob/ob mice (8).
Obesity remains a daunting problem. The current re-
sults, however, support the notion that starving adipose
tissue of its necessary vasculature results in profound
reductions in body weight and body fat. Of particular
interest in the present studies is that administering a
peptide designed to cause apoptosis in endothelial cells
uniquely in white adipose tissue results in a reduction in
caloric intake. Although the mechanism by which food
intake is reduced remains unclear, it occurs despite falling
levels of leptin. The phenomenon extends to changes in
hypothalamic gene expression that are consistent with the
overall negative energy balance and cannot explain the
effect of the proapoptotic peptide to reduce food intake.
Consequently, these data imply the existence of a novel
component of the regulation of energy balance that re-
ﬂects the status of white adipose tissue vasculature and is
sufﬁciently potent to override signals derived from low-
circulating leptin levels. Understanding these novel signals
may provide entirely new approaches to producing safe
and efﬁcacious weight loss.
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